November 02, 2016
1 min read
Save

ACR, EULAR approve classification criteria for Sjögren’s syndrome

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Using a methodology consistent with previous ACR and EULAR criteria, an international group of researchers developed and validated a new set of classification criteria for primary Sjögren’s syndrome, which was then approved by the ACR and EULAR.

Caroline H. Shiboski, DDS, PhD, at the University of California, San Francisco School of Dentistry, and colleagues used existing cohort data to derive classification criteria based on the following five items:

  • anti-Sjögren’s-syndrome-related antigen A (anti-SSA/Ro) antibody positivity;
  • focal lymphocytic sialadenitis with a focus score of at least 1 foci per 4 mm2;
  • abnormal ocular staining score of at least 5 or a van Bijsterveld score of at least 4;
  • Schimer’s test result of no greater than 5 mm per 5 minutes; and
  • an unstimulated salivary flow rate of no greater than 0.1 mL per minute.

The anti-SSA/Ro and sialadenitis items received a weight of three, while the remaining three items received a weight of one. Individuals with signs or symptoms of Sjogren’s syndrome (SS) and who have a total score of at least 4 for the above items meet the criteria for primary SS.

In the validation cohort, the criteria had a sensitivity of 96% and a specificity of 95%.

“The primary application of classification criteria is recruitment in clinical trials and studies,” the researchers wrote. “Although our study focused on classification of primary SS, the proposed criteria may be applicable to SS associated with other autoimmune diseases. – by Will Offit

Disclosure: Shiboski reports consulting fees from the Pasteur Institute. Please see the full study for a list of all other relevant financial disclosures.